The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Preliminary data on the effectiveness of the novel BTK degrader BGB-16673 in R/R CLL
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, comments on the promising results of the novel BTK degrader BGB-16673 in treating relapsed/refractory chronic lymphocytic leukemia (CLL). Dr Scarfò highlights that preliminary data suggests that it is effective even in heavily pretreated patients. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
At this meeting we presented the updated results of this novel drug called BGB-16673 that is acting by a degradation of BTK. So it’s a BTK degrader, it’s targeting BTK and leading to the polyubiquitination and then proteasomal degradation within the cells of the protein. And we are now working on this drug in the setting of patients with relapsed/refractory CLL and there are preliminary data suggesting that the drug might work even in heavily pretreated patients including patients exposed to covalent BTK inhibitor, BCL2 inhibitor and non-covalent BCL2 inhibitor...
At this meeting we presented the updated results of this novel drug called BGB-16673 that is acting by a degradation of BTK. So it’s a BTK degrader, it’s targeting BTK and leading to the polyubiquitination and then proteasomal degradation within the cells of the protein. And we are now working on this drug in the setting of patients with relapsed/refractory CLL and there are preliminary data suggesting that the drug might work even in heavily pretreated patients including patients exposed to covalent BTK inhibitor, BCL2 inhibitor and non-covalent BCL2 inhibitor. So it’s a phase I/II study. We have initial data but they look very promising. So I hope that in the next future we can add this additional drug to our therapeutic armamentarium in CLL.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
